Inhibikase Therapeutics, Inc. (IKT) Q3 2023 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to the HEMPA Case Therapeutics Third Quarter 2023 Financial Results. All participants will be in this anomaly mode. Should you need assistance, please send to a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your touch-tone phone. To withdraw your question, please press star, then two. Please note, today's event is being recorded. I now turn the conference over to Alexander Lobo of Stern Investor Relations. Please go ahead, sir. Thank you, operator. Good morning, and welcome to Inhibit Case Therapeutics Third Quarter 2023 Financial Results Conference Call and Audio Webcast. With me today is Dr. Milton Werner, Chief Executive Officer, and Joseph Frateroli, Chief Financial Officer. On Tuesday, November 14, 2023, Inhibit Case issued a press release announcing financial results but the third quarter ended September 30th, 2023. We encourage everyone to read yesterday's press release, as well as Inhibit Case's quarterly report on Form 10-Q, which is being filed with the SEC. The company's press release and quarterly report are also available on Inhibit Case's website at inhibitcase.com. In addition, this conference call is being webcast through the investor relations section of the company's website and will be archived there for future reference. Please note that certain information discussed on today's call is covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Participants are cautioned that this conference call contains time-sensitive information that is accurate only as of the date of this live broadcast, November 15, 2023. Actual results could differ materially ...